Belgium and Netherlands Advance Wound Care Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2024
In this region, Belgium advanced wound care market is projected to reach USD 28.0 million by 2024 from USD 22.6 million in 2016, at a CAGR of 2.8% in the forecast period 2017 to 2024. Netherlands advanced wound care market is projected to reach USD 167.9 million by 2024 from USD 135.4 million in 2016, at a CAGR of 2.8% in the forecast period 2017 to 2024.
Some of the major players operating in this market are
Dressing is further segmented into foam dressings, hydrogels, film dressings, alginates, wound contact layer, and super absorbent dressing. Also, biologics market is further segmented into synthetic skin grafts, growth factors, allografts, and xenografts.
The therapy devices are further segmented into negative pressure wound therapy, pressure relief devices (PRD), wound debridement devices, hyperbaric oxygen chambers, and physical therapies.
The growth factors are further divided into platelet-derived growth factor (PDGF), platelet rich plasma (PRP), epidermal growth factor (EGF), basic fibroblast growth factor (BFGF), granulocyte colony stimulating factor (G-CSF), Talactoferrin ALFA, thrombin peptide (TP508), and keratinocyte growth factor (KGF).
The negative pressure wound therapy (NPWT) is further classified into standalone NPWT devices, portable NPWT devices, and disposable NPWT devices. The pressure relief devices (PRD) are further classified into mattress and bed.
The hyperbaric oxygen chambers are further classified into monoplace, multiplace, and topical. The wound debridement devices are further classified into hydrosurgical, ultrasound, mechanical, and others. The physical therapies are further classified into laser therapy, electrical stimulation, external shock wave therapies (ESWT), and saline mist therapy.
On the basis of wound type, the Belgium and Netherlands advance wound care market is segmented into surgical wound, diabetic ulcers, burns, pressure ulcers, venous ulcers and others.
On the basis of end users, the Belgium and Netherlands advance wound care marketis segmented into hospitals, wound care centers, ambulatory centers, home healthcare, clinics and community healthcare.
On the basis of distribution channel, the Belgium and Netherlands advance wound care marketis segmented into direct tenders and retailers.
Some of the major players operating in this market are
- Acelity L.P. INC
- Smith and Nephew
- Molnlycke, Convatec INC.
- 3M
- Baxter
- Coloplast
- Ethicon INC.
- Paul Hartmann Limited
Dressing is further segmented into foam dressings, hydrogels, film dressings, alginates, wound contact layer, and super absorbent dressing. Also, biologics market is further segmented into synthetic skin grafts, growth factors, allografts, and xenografts.
The therapy devices are further segmented into negative pressure wound therapy, pressure relief devices (PRD), wound debridement devices, hyperbaric oxygen chambers, and physical therapies.
The growth factors are further divided into platelet-derived growth factor (PDGF), platelet rich plasma (PRP), epidermal growth factor (EGF), basic fibroblast growth factor (BFGF), granulocyte colony stimulating factor (G-CSF), Talactoferrin ALFA, thrombin peptide (TP508), and keratinocyte growth factor (KGF).
The negative pressure wound therapy (NPWT) is further classified into standalone NPWT devices, portable NPWT devices, and disposable NPWT devices. The pressure relief devices (PRD) are further classified into mattress and bed.
The hyperbaric oxygen chambers are further classified into monoplace, multiplace, and topical. The wound debridement devices are further classified into hydrosurgical, ultrasound, mechanical, and others. The physical therapies are further classified into laser therapy, electrical stimulation, external shock wave therapies (ESWT), and saline mist therapy.
On the basis of wound type, the Belgium and Netherlands advance wound care market is segmented into surgical wound, diabetic ulcers, burns, pressure ulcers, venous ulcers and others.
On the basis of end users, the Belgium and Netherlands advance wound care marketis segmented into hospitals, wound care centers, ambulatory centers, home healthcare, clinics and community healthcare.
On the basis of distribution channel, the Belgium and Netherlands advance wound care marketis segmented into direct tenders and retailers.
1. INTRODUCTION
1.1 OVERVIEW OF THE BELGIUM AND NETHERLANDS ADVANCED WOUND CARE MARKET
1.2 CURRENCY AND PRICING
1.3 LIMITATION
1.4 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE BELGIUM AND NETHERLANDS ADVANCED WOUND CARE MARKET
2.2.1 MARKET CRACKDOWN APPROACH
2.2.2 COMPANY REVENUE AND MARKET SHARE ANALYSIS
2.2.3 DATA TRIANGULATION
2.2.4 KEY DATA POINTS FROM PRIMARY SOURCES
2.2.5 KEY DATA POINTS FROM SECONDARY SOURCES
2.2.6 PORTER’S FIVE FORCES MATRIX
2.2.7 PEST ANALYSIS
2.2.8 EPIDEMIOLOGY FORECASTING MODELS
2.3 BELGIUM AND NETHERLANDS ADVANCED WOUND CARE MARKET:RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
6 BELGIUM AND NETHERLANDS ADVANCED WOUND CARE MARKET, BY TYPE
6.1 OVERVIEW
6.2 DRESSINGS
6.3 BIOLOGICS
6.4 THERAPY DEVICES
7 BELGIUM AND NETHERLANDS ADVANCED WOUND CARE MARKET, BY WOUND TYPE
7.1 OVERVIEW
7.2 SURGICAL WOUNDS
7.3 DIABETIC ULCERS
7.4 PRESSURE ULCERS
7.5 VENOUS ULCERS
7.6 BURNS
7.7 OTHER TRAUMATIC WOUNDS
8 BELGIUM AND NETHERLANDS ADVANCED WOUND CARE MARKET, BY END USER
8.1 OVERVIEW
8.2 HOSPITALS
8.3 WOUND CARE CENTERS
8.4 AMBULATORY CENTERS
8.5 CLINICS
8.6 COMMUNITY HEALTHCARE
8.7 HOME HEALTHCARE
9 BELGIUM AND NETHERLANDS ADVANCED WOUND CARE MARKET, BY ISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 DIRECT TENDERS PUBLIC
9.3 RETAIL PRIVATE
10 BELGIUM AND NETHERLANDS ADVANCED WOUND CARE MARKET, BY COUNTRY
10.1 COUNTRYWISE BELGIUM AND NETHERLANDS ADVANCED WOUND CARE MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
10.1.1 BELGIUM
10.1.2 NETHERLANDS
10.2 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
11 BELGIUM ADVANCED WOUND CARE MARKET: COMPETITIVE LANDSCAPE
11.1. BELGIUM ADVANCED WOUND CARE MARKET: COMPANY SHARE ANALYSIS
11.2. MERGERS & ACQUISITIONS
11.3. NEW PRODUCT DEVELOPMENT & APPROVALS
11.4. EXPANSIONS
11.5. REGULATORY CHANGES
11.6. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
12 NETHERLANDS ADVANCED WOUND CARE MARKET: COMPETITIVE LANDSCAPE
12.1. NETHERLANDS ADVANCED WOUND CARE MARKET: COMPANY SHARE ANALYSIS
12.2. MERGERS & ACQUISITIONS
12.3. NEW PRODUCT DEVELOPMENT & APPROVALS
12.4. EXPANSIONS
12.5. REGULATORY CHANGES
12.6. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
13 BELGIUM AND NETHERLANDS ADVANCED WOUND CARE MARKET, COMPANY PROFILES
13.1 3M
13.1.1 COMPANY OVERVIEW
13.1.2 FINANCIAL ANALYSIS
13.1.3 PRODUCT MATRIX
13.1.4 RECENT DEVELOPMENTS
13.1.5 DATABRIDGE ANALYSIS
13.2 SMITH AND NEPHEW
13.2.1 COMPANY OVERVIEW
13.2.2 FINANCIAL ANALYSIS
13.2.3 PRODUCT MATRIX
13.2.4 RECENT DEVELOPMENTS
13.2.5 DATABRIDGE ANALYSIS
13.3 MEDTRONIC
13.3.1 COMPANY OVERVIEW
13.3.2 FINANCIAL ANALYSIS
13.3.3 PRODUCT MATRIX
13.3.4 RECENT DEVELOPMENTS
13.3.5 DATABRIDGE ANALYSIS
13.4 MOLNLYCKE HEALTHCARE AB
13.4.1 COMPANY OVERVIEW
13.4.2 FINANCIAL ANALYSIS
13.4.3 PRODUCT MATRIX
13.4.4 RECENT DEVELOPMENTS
13.4.5 DATABRIDGE ANALYSIS
13.5 CONVATEC INC
13.5.1 COMPANY OVERVIEW
13.5.2 FINANCIAL ANALYSIS
13.5.3 PRODUCT MATRIX
13.5.4 RECENT DEVELOPMENTS
13.5.5 DATABRIDGE ANALYSIS
13.6 BAXTER
13.6.1 COMPANY OVERVIEW
13.6.2 FINANCIAL ANALYSIS
13.6.3 PRODUCT MATRIX
13.6.4 RECENT DEVELOPMENTS
13.6.5 DATABRIDGE ANALYSIS
13.7 COLOPLAST
13.7.1 COMPANY OVERVIEW
13.7.2 FINANCIAL ANALYSIS
13.7.3 PRODUCT MATRIX
13.7.4 RECENT DEVELOPMENTS
13.7.5 DATABRIDGE ANALYSIS
13.8 ETHICON. INC
13.8.1 COMPANY OVERVIEW
13.8.2 FINANCIAL ANALYSIS
13.8.3 PRODUCT MATRIX
13.8.4 RECENT DEVELOPMENTS
13.8.5 DATABRIDGE ANALYSIS
13.9 INTEGRA LIFE SCIENCES CORPORATION
13.9.1 COMPANY OVERVIEW
13.9.2 FINANCIAL ANALYSIS
13.9.3 PRODUCT MATRIX
13.9.4 RECENT DEVELOPMENTS
13.9.5 DATABRIDGE ANALYSIS
13.10 HOLLISTER INC
13.10.1 COMPANY OVERVIEW
13.10.2 FINANCIAL ANALYSIS
13.10.3 PRODUCT MATRIX
13.10.4 RECENT DEVELOPMENTS
13.10.5 DATABRIDGE ANALYSIS
13.11 B. BRAUN MELSUNGEN AG
13.11.1 COMPANY OVERVIEW
13.11.2 FINANCIAL ANALYSIS
13.11.3 PRODUCT MATRIX
13.11.4 RECENT DEVELOPMENTS
13.11.5 DATABRIDGE ANALYSIS
13.12 MEDLINE INDUSTRIES
13.12.1 COMPANY OVERVIEW
13.12.2 FINANCIAL ANALYSIS
13.12.3 PRODUCT MATRIX
13.12.4 RECENT DEVELOPMENTS
13.12.5 DATABRIDGE ANALYSIS
13.13 MIMEDX GROUP
13.13.1 COMPANY OVERVIEW
13.13.2 FINANCIAL ANALYSIS
13.13.3 PRODUCT MATRIX
13.13.4 RECENT DEVELOPMENTS
13.13.5 DATABRIDGE ANALYSIS
13.14 ORGANO GENESIS INC
13.14.1 COMPANY OVERVIEW
13.14.2 FINANCIAL ANALYSIS
13.14.3 PRODUCT MATRIX
13.14.4 RECENT DEVELOPMENTS
13.14.5 DATABRIDGE ANALYSIS
13.15 TALLEY GROUP LIMITED
13.15.1 COMPANY OVERVIEW
13.15.2 FINANCIAL ANALYSIS
13.15.3 PRODUCT MATRIX
13.15.4 RECENT DEVELOPMENTS
13.15.5 DATABRIDGE ANALYSIS
13.16 BSN MEDICAL
13.16.1 COMPANY OVERVIEW
13.16.2 FINANCIAL ANALYSIS
13.16.3 PRODUCT MATRIX
13.16.4 RECENT DEVELOPMENTS
13.16.5 DATABRIDGE ANALYSIS
13.17 DEVON MEDICAL PRODUCTS
13.17.1 COMPANY OVERVIEW
13.17.2 FINANCIAL ANALYSIS
13.17.3 PRODUCT MATRIX
13.17.4 RECENT DEVELOPMENTS
13.17.5 DATABRIDGE ANALYSIS
13.18 HUMAN BIOSCIENCES INC
13.18.1 COMPANY OVERVIEW
13.18.2 FINANCIAL ANALYSIS
13.18.3 PRODUCT MATRIX
13.18.4 RECENT DEVELOPMENTS
13.18.5 DATABRIDGE ANALYSIS
13.19 ADVANCIS MEDICAL
13.19.1 COMPANY OVERVIEW
13.19.2 FINANCIAL ANALYSIS
13.19.3 PRODUCT MATRIX
13.19.4 RECENT DEVELOPMENTS
13.19.5 DATABRIDGE ANALYSIS
13.20 CARDINAL HEALTH
13.20.1 COMPANY OVERVIEW
13.20.2 FINANCIAL ANALYSIS
13.20.3 PRODUCT MATRIX
13.20.4 RECENT DEVELOPMENTS
13.20.5 DATABRIDGE ANALYSIS
13.21 PAUL HARTMANN LIMITED
13.21.1 COMPANY OVERVIEW
13.21.2 FINANCIAL ANALYSIS
13.21.3 PRODUCT MATRIX
13.21.4 RECENT DEVELOPMENTS
13.21.5 DATABRIDGE ANALYSIS
13.22 DEROYAL INDUSTRIES INC
13.22.1 COMPANY OVERVIEW
13.22.2 FINANCIAL ANALYSIS
13.22.3 PRODUCT MATRIX
13.22.4 RECENT DEVELOPMENTS
13.22.5 DATABRIDGE ANALYSIS
13.23 PAUL HARTMANN LIMITED
13.23.1 COMPANY OVERVIEW
13.23.2 FINANCIAL ANALYSIS
13.23.3 PRODUCT MATRIX
13.23.4 RECENT DEVELOPMENTS
13.23.5 DATABRIDGE ANALYSIS
13.24 DERMARITE INDUSTRIES LLC
13.24.1 COMPANY OVERVIEW
13.24.2 FINANCIAL ANALYSIS
13.24.3 PRODUCT MATRIX
13.24.4 RECENT DEVELOPMENTS
13.24.5 DATABRIDGE ANALYSIS
14 APPENDIX
15 ABOUT DATA BRIDGE MARKET RESEARCH
1.1 OVERVIEW OF THE BELGIUM AND NETHERLANDS ADVANCED WOUND CARE MARKET
1.2 CURRENCY AND PRICING
1.3 LIMITATION
1.4 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE BELGIUM AND NETHERLANDS ADVANCED WOUND CARE MARKET
2.2.1 MARKET CRACKDOWN APPROACH
2.2.2 COMPANY REVENUE AND MARKET SHARE ANALYSIS
2.2.3 DATA TRIANGULATION
2.2.4 KEY DATA POINTS FROM PRIMARY SOURCES
2.2.5 KEY DATA POINTS FROM SECONDARY SOURCES
2.2.6 PORTER’S FIVE FORCES MATRIX
2.2.7 PEST ANALYSIS
2.2.8 EPIDEMIOLOGY FORECASTING MODELS
2.3 BELGIUM AND NETHERLANDS ADVANCED WOUND CARE MARKET:RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
6 BELGIUM AND NETHERLANDS ADVANCED WOUND CARE MARKET, BY TYPE
6.1 OVERVIEW
6.2 DRESSINGS
6.3 BIOLOGICS
6.4 THERAPY DEVICES
7 BELGIUM AND NETHERLANDS ADVANCED WOUND CARE MARKET, BY WOUND TYPE
7.1 OVERVIEW
7.2 SURGICAL WOUNDS
7.3 DIABETIC ULCERS
7.4 PRESSURE ULCERS
7.5 VENOUS ULCERS
7.6 BURNS
7.7 OTHER TRAUMATIC WOUNDS
8 BELGIUM AND NETHERLANDS ADVANCED WOUND CARE MARKET, BY END USER
8.1 OVERVIEW
8.2 HOSPITALS
8.3 WOUND CARE CENTERS
8.4 AMBULATORY CENTERS
8.5 CLINICS
8.6 COMMUNITY HEALTHCARE
8.7 HOME HEALTHCARE
9 BELGIUM AND NETHERLANDS ADVANCED WOUND CARE MARKET, BY ISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 DIRECT TENDERS PUBLIC
9.3 RETAIL PRIVATE
10 BELGIUM AND NETHERLANDS ADVANCED WOUND CARE MARKET, BY COUNTRY
10.1 COUNTRYWISE BELGIUM AND NETHERLANDS ADVANCED WOUND CARE MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
10.1.1 BELGIUM
10.1.2 NETHERLANDS
10.2 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
11 BELGIUM ADVANCED WOUND CARE MARKET: COMPETITIVE LANDSCAPE
11.1. BELGIUM ADVANCED WOUND CARE MARKET: COMPANY SHARE ANALYSIS
11.2. MERGERS & ACQUISITIONS
11.3. NEW PRODUCT DEVELOPMENT & APPROVALS
11.4. EXPANSIONS
11.5. REGULATORY CHANGES
11.6. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
12 NETHERLANDS ADVANCED WOUND CARE MARKET: COMPETITIVE LANDSCAPE
12.1. NETHERLANDS ADVANCED WOUND CARE MARKET: COMPANY SHARE ANALYSIS
12.2. MERGERS & ACQUISITIONS
12.3. NEW PRODUCT DEVELOPMENT & APPROVALS
12.4. EXPANSIONS
12.5. REGULATORY CHANGES
12.6. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
13 BELGIUM AND NETHERLANDS ADVANCED WOUND CARE MARKET, COMPANY PROFILES
13.1 3M
13.1.1 COMPANY OVERVIEW
13.1.2 FINANCIAL ANALYSIS
13.1.3 PRODUCT MATRIX
13.1.4 RECENT DEVELOPMENTS
13.1.5 DATABRIDGE ANALYSIS
13.2 SMITH AND NEPHEW
13.2.1 COMPANY OVERVIEW
13.2.2 FINANCIAL ANALYSIS
13.2.3 PRODUCT MATRIX
13.2.4 RECENT DEVELOPMENTS
13.2.5 DATABRIDGE ANALYSIS
13.3 MEDTRONIC
13.3.1 COMPANY OVERVIEW
13.3.2 FINANCIAL ANALYSIS
13.3.3 PRODUCT MATRIX
13.3.4 RECENT DEVELOPMENTS
13.3.5 DATABRIDGE ANALYSIS
13.4 MOLNLYCKE HEALTHCARE AB
13.4.1 COMPANY OVERVIEW
13.4.2 FINANCIAL ANALYSIS
13.4.3 PRODUCT MATRIX
13.4.4 RECENT DEVELOPMENTS
13.4.5 DATABRIDGE ANALYSIS
13.5 CONVATEC INC
13.5.1 COMPANY OVERVIEW
13.5.2 FINANCIAL ANALYSIS
13.5.3 PRODUCT MATRIX
13.5.4 RECENT DEVELOPMENTS
13.5.5 DATABRIDGE ANALYSIS
13.6 BAXTER
13.6.1 COMPANY OVERVIEW
13.6.2 FINANCIAL ANALYSIS
13.6.3 PRODUCT MATRIX
13.6.4 RECENT DEVELOPMENTS
13.6.5 DATABRIDGE ANALYSIS
13.7 COLOPLAST
13.7.1 COMPANY OVERVIEW
13.7.2 FINANCIAL ANALYSIS
13.7.3 PRODUCT MATRIX
13.7.4 RECENT DEVELOPMENTS
13.7.5 DATABRIDGE ANALYSIS
13.8 ETHICON. INC
13.8.1 COMPANY OVERVIEW
13.8.2 FINANCIAL ANALYSIS
13.8.3 PRODUCT MATRIX
13.8.4 RECENT DEVELOPMENTS
13.8.5 DATABRIDGE ANALYSIS
13.9 INTEGRA LIFE SCIENCES CORPORATION
13.9.1 COMPANY OVERVIEW
13.9.2 FINANCIAL ANALYSIS
13.9.3 PRODUCT MATRIX
13.9.4 RECENT DEVELOPMENTS
13.9.5 DATABRIDGE ANALYSIS
13.10 HOLLISTER INC
13.10.1 COMPANY OVERVIEW
13.10.2 FINANCIAL ANALYSIS
13.10.3 PRODUCT MATRIX
13.10.4 RECENT DEVELOPMENTS
13.10.5 DATABRIDGE ANALYSIS
13.11 B. BRAUN MELSUNGEN AG
13.11.1 COMPANY OVERVIEW
13.11.2 FINANCIAL ANALYSIS
13.11.3 PRODUCT MATRIX
13.11.4 RECENT DEVELOPMENTS
13.11.5 DATABRIDGE ANALYSIS
13.12 MEDLINE INDUSTRIES
13.12.1 COMPANY OVERVIEW
13.12.2 FINANCIAL ANALYSIS
13.12.3 PRODUCT MATRIX
13.12.4 RECENT DEVELOPMENTS
13.12.5 DATABRIDGE ANALYSIS
13.13 MIMEDX GROUP
13.13.1 COMPANY OVERVIEW
13.13.2 FINANCIAL ANALYSIS
13.13.3 PRODUCT MATRIX
13.13.4 RECENT DEVELOPMENTS
13.13.5 DATABRIDGE ANALYSIS
13.14 ORGANO GENESIS INC
13.14.1 COMPANY OVERVIEW
13.14.2 FINANCIAL ANALYSIS
13.14.3 PRODUCT MATRIX
13.14.4 RECENT DEVELOPMENTS
13.14.5 DATABRIDGE ANALYSIS
13.15 TALLEY GROUP LIMITED
13.15.1 COMPANY OVERVIEW
13.15.2 FINANCIAL ANALYSIS
13.15.3 PRODUCT MATRIX
13.15.4 RECENT DEVELOPMENTS
13.15.5 DATABRIDGE ANALYSIS
13.16 BSN MEDICAL
13.16.1 COMPANY OVERVIEW
13.16.2 FINANCIAL ANALYSIS
13.16.3 PRODUCT MATRIX
13.16.4 RECENT DEVELOPMENTS
13.16.5 DATABRIDGE ANALYSIS
13.17 DEVON MEDICAL PRODUCTS
13.17.1 COMPANY OVERVIEW
13.17.2 FINANCIAL ANALYSIS
13.17.3 PRODUCT MATRIX
13.17.4 RECENT DEVELOPMENTS
13.17.5 DATABRIDGE ANALYSIS
13.18 HUMAN BIOSCIENCES INC
13.18.1 COMPANY OVERVIEW
13.18.2 FINANCIAL ANALYSIS
13.18.3 PRODUCT MATRIX
13.18.4 RECENT DEVELOPMENTS
13.18.5 DATABRIDGE ANALYSIS
13.19 ADVANCIS MEDICAL
13.19.1 COMPANY OVERVIEW
13.19.2 FINANCIAL ANALYSIS
13.19.3 PRODUCT MATRIX
13.19.4 RECENT DEVELOPMENTS
13.19.5 DATABRIDGE ANALYSIS
13.20 CARDINAL HEALTH
13.20.1 COMPANY OVERVIEW
13.20.2 FINANCIAL ANALYSIS
13.20.3 PRODUCT MATRIX
13.20.4 RECENT DEVELOPMENTS
13.20.5 DATABRIDGE ANALYSIS
13.21 PAUL HARTMANN LIMITED
13.21.1 COMPANY OVERVIEW
13.21.2 FINANCIAL ANALYSIS
13.21.3 PRODUCT MATRIX
13.21.4 RECENT DEVELOPMENTS
13.21.5 DATABRIDGE ANALYSIS
13.22 DEROYAL INDUSTRIES INC
13.22.1 COMPANY OVERVIEW
13.22.2 FINANCIAL ANALYSIS
13.22.3 PRODUCT MATRIX
13.22.4 RECENT DEVELOPMENTS
13.22.5 DATABRIDGE ANALYSIS
13.23 PAUL HARTMANN LIMITED
13.23.1 COMPANY OVERVIEW
13.23.2 FINANCIAL ANALYSIS
13.23.3 PRODUCT MATRIX
13.23.4 RECENT DEVELOPMENTS
13.23.5 DATABRIDGE ANALYSIS
13.24 DERMARITE INDUSTRIES LLC
13.24.1 COMPANY OVERVIEW
13.24.2 FINANCIAL ANALYSIS
13.24.3 PRODUCT MATRIX
13.24.4 RECENT DEVELOPMENTS
13.24.5 DATABRIDGE ANALYSIS
14 APPENDIX
15 ABOUT DATA BRIDGE MARKET RESEARCH
